Increased heparin binding by site directed mutagenesis of a recombinant chimera of bombyxin and insulin-like growth factor II.
BOMIGF, a chimera between bombyxin and insulin-like growth factor II (IGF II) has been modified and extended to a total of 85 amino acids including 7 additional basic amino acids. The new peptide bound heparin as efficiently as GM-CSF and much better than IGF II or BOMIGF. It could be retained on albumin-coated tissue culture wells without loosing its capacity to stimulate thymidine incorporation into erythroid cells of fetal bovine liver and on fibronectin-heparin coated wells keeping its mitogenic activity towards L6 muscle cells.